FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems

What's New on the FDA Drugs Site
July 26, 2013

• Drug Firm Annual Registration Status (updated)
• Drug Firm Annual Registration Status Download File (updated)
• Guidance for Industry:Guidance Agenda: New & Revised Draft Guidances CDER is  Planning to Publish During Calendar Year 2013 (PDF - 40KB)
• FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems
• Medication Guides (updated)
• National Drug Code Directory